California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.

(READ MORE)

CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”

(READ MORE)

U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.

(READ MORE)

Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.

(READ MORE)

Fire & Flower has tons of upside, says AltaCorp Capital

A new deal with a major POS company for the cannabis sector bodes well for retailer Fire & Flower (Fire & Flower Stock Quote, Chart, News TSX:FAF), says AltaCorp Capital analyst David Kideckel, who in a client update on Monday said that retail not production and cultivation is t...

Sex Drive and The Endocannabinoid System

He once told me that he knew he was in trouble as soon as I looked at him. I knew the look because I remember the thoughts behind it. We were high school hot for each other and when we finally got a hold of each other, we didn’t let go for hours. Then, one […] The post Sex D...

TSX has worst day in nearly four months on concerns about coronavirus impact

TORONTO — Canada’s main stock index TSX had its worst day in nearly four months to start the week as stock markets around the world tumbled on worries that economic growth will be hurt by the coronavirus outbreak in China. The S&P/TSX composite index closed down 122.82 point...

High Tide acquires top-performing Canna Cabana retail Store

CALGARY, Jan. 27, 2020 /CNW/ – High Tide Inc. (“High Tide” or the “Company”) (CSE:HITI) (OTCQB:HITIF) (Frankfurt:2LY), an Alberta-based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis li...

Fire & Flower and Hifyre announce an agreement with Cova point of sale software

EDMONTON, Jan. 27, 2020 /CNW/ – Fire & Flower Holdings Corp. (“Fire & Flower”, the “Company”, or “FFHC”) and its indirect wholly-owned subsidiary HifyreTM Inc. (“Hifyre”), today announced that it has entered into a Strategic Licence Agreement (the “Agreemen...

Inside Kalya Extracts, the Emerald Cup-Winning Hash Company

A month after sweeping the podium in the world’s most competitive solventless hash competition at The Emerald Cup, Kalya Extracts now gives Oakland, California a solid claim to producing the best hash on the planet.  Kalya Extracts’ big winners this year in the solventles...

Buy Cresco Labs for 182 per cent upside: Beacon Securities

A new term loan for US cannabis play Cresco Labs (Cresco Labs Stock Quote, Chart, News CSE:CL) was given the thumbs up by Beacon Securities analyst Russell Stanley on Thursday as the analyst reaffirmed his “Buy” rating and C$24.00 target for Cresco, saying that the company h...

Assessing the market impact of the Wuhan coronavirus

The outbreak of novel coronavirus in Wuhan, China, and in pockets around the world has garnered significant public concern, and the global financial market is on edge. We have received numerous questions about the potential impact to investors and how the economic effects of the...

Trade secrets and forbidden solvents in today’s cannabis extracts

Botanical extraction is used in various industries from cosmetics to cleaning products, and of course in food. We recently detailed six of the most common methods of extraction used in the cannabis industry, and a total of nine permitted solvents. Yet, Health Canada has approved...

Illinois: More People Apply for Medical Marijuana To Avoid Paying High Taxes

Think about the tax revenue we could generate from the legalization of marijuana. That’s the spiel the cannabis advocacy community has been selling for decades to get a square nation to embrace greener times. But now that lawmakers are starting to listen to the cries — movin...